CytoDyn, Inc. (CYDY)
Stock Price:
$2.67 USD
0.00 (0.00%)
Updated November 25, 3:59 PM EST - Market closed
Key Info
| Market Cap |
1.52B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-139.07M |
| Shares Out |
570.75M |
| EPS (ttm) |
-0.30 |
| PE Ratio |
n/a |
| Forward PE |
10.81 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$2.67 |
| Previous Close |
$2.67 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
2.67 |
| Day's Range |
2.63 - 2.69 |
| Day's Volume |
1,180,182 |
| 52-Week Range |
0.261 - 10.01 |
More Stats
| Market Cap |
1.52B |
| Enterprise Value |
1.54B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
570.75M |
| Float |
499.88M |
| EPS (basic) |
-0.31 |
| EPS (diluted) |
-0.30 |
| FCF / Share |
-0.17 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
-0.87 |
| PE Ratio |
n/a |
| Forward PE |
10.81 |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
525.80 |
| Revenue |
n/a |
| Operating Income |
-87.58M |
| Net Income |
-139.07M |
| Free Cash Flow |
-94.66M |
| Net Cash |
-14.19M |
| Net Cash / Share |
-0.02 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-97.97% |
| ROE |
n/a |
| ROIC |
1,977.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.00
Current: $2.67
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -74.65 | -55.85 | -45.92 | -27.33 | -21.18 | -19.60 | -8.11 | -7.99 | -7.46 | -3.70 |
| Net Income | -124 | -56.19 | -50.15 | -25.76 | -25.70 | -25.09 | -12.43 | -9.57 | -7.47 | -3.72 |
| Shares Outstanding | 421 | 272 | 175 | 138 | 95.44 | 58.38 | 46.90 | 29.94 | 24.62 | 21.08 |
| Earnings Per Share | -0.30 | -0.21 | -0.29 | -0.19 | -0.27 | -0.43 | -0.27 | -0.32 | -0.31 | -0.18 |
| Operating Cash Flow | -68.80 | -50.47 | -29.90 | -26.73 | -24.81 | -12.02 | -7.39 | -3.39 | -4.39 | -1.82 |
| Capital Expenditures | -0.04 | -0.03 | - | -0.01 | -0.01 | -0.02 | -0.02 | - | - | - |
| Free Cash Flow | -68.84 | -50.49 | -29.90 | -26.74 | -24.82 | -12.04 | -7.41 | -3.40 | -4.39 | -1.83 |
| Cash & Equivalents | 14.29 | 3.47 | 1.23 | 1.78 | 9.64 | 1.05 | 4.89 | 0.60 | 0.28 | 1.04 |
| Total Debt | 15.35 | 8.24 | - | 1.06 | - | 4.27 | 2.34 | 1.99 | 0.08 | 0.16 |
| Net Cash / Debt | -1.06 | -4.77 | 1.23 | 0.72 | 9.64 | -3.22 | 2.55 | -1.39 | 0.20 | 0.88 |
| Assets | 50.51 | 20.87 | 4.90 | 8.06 | 13.79 | 4.68 | 8.43 | 4.16 | 1.07 | 1.99 |
| Liabilities | 53.00 | 29.79 | 18.06 | 9.16 | 3.58 | 15.37 | 4.51 | 4.38 | 5.04 | 7.00 |
| Book Value | -2.48 | -8.91 | -13.16 | -1.10 | 10.21 | -10.69 | 3.92 | -0.22 | -3.97 | -5.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CytoDyn, Inc. |
| Country |
United States |
| Employees |
19 |
| CEO |
Nader Z. Pourhassan |
Stock Information
| Ticker Symbol |
CYDY |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: CYDY |
Description
CytoDyn, a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.